Analysis of PD-L1 Expression by Combined Positive Score May Help Identify Which Patients with Advanced Gastric/Gastroesophageal Junction Cancer Will Respond to Treatment with Nivolumab and Ipilimumab

Web Exclusives - Gastrointestinal Cancers

The third leading cause of cancer-related mortality is gastric cancer and gastroesophageal junction (GEJ) cancer. Most cases are diagnosed at an advanced stage, giving patients an overall poor survival rate if they do not receive treatment. Even with standard treatment, most patients will experience disease progression. This leaves patients with limited treatment options, making the search for new therapies imperative. One avenue of investigational approach is the study of biomarkers that can indicate which tumors may respond to a particular treatment. Lei and colleagues conducted a post-hoc analysis of the gastric/GEJ cohort from the CheckMate-032 clinical trial to evaluate biomarkers that correlated with clinical response to treatment with nivolumab plus ipilimumab.

In the CheckMate-032 study, participants had ≥1 prior chemotherapy regimens and no previous T-cell co-stimulation immune checkpoint inhibitor or antitumor vaccine therapy. Patients were treated with either nivolumab monotherapy or nivolumab in combination with ipilimumab, followed by maintenance nivolumab monotherapy. PD-L1 expression was determined and reported as the percentage of positive tumor cells (%TC). PD-L1 according to combined positive score (CPS) was also determined. In addition, gene expression profiling of 9 inflammatory gene expression signatures or individual transcripts were evaluated during this analysis, including a 4-gene inflammatory signature consisting of CD274 (PD-L1), CD8A, LAG3, and STAT1. There were 40 patients evaluated in this analysis. The evaluation explored the association of PD-L1 expression on tumor and immune cells and inflammatory gene expression signatures with efficacy of nivolumab plus ipilimumab in patients with gastric cancer or GEJ cancer. Efficacy was assessed by evaluating objective responses, objective response rate (ORR), and overall survival.

In the pooled analysis of all treatment regimens, the ORR was 19% for patients with PD-L1–positive tumors with a CPS cutoff of ≥5 and 26% for patients with CPS cutoff ≥10. The ORR was 8% for patients with an equivalent %TC cutoff ≥5 and 9% for patients with an equivalent %TC cutoff ≥10. A longer survival was found in patients with PD-L1–positive versus PD-L1–negative status. In addition, 7 inflammatory gene signature/transcripts, including the 4-gene inflammatory signature, demonstrated associations with a response to nivolumab and ipilimumab.

The post-hoc analysis found a greater association with nivolumab plus ipilimumab therapy efficacy for PD-L1 expression by CPS compared with %TC PD-L1 expression in patients with advanced gastric or GEJ cancer, which may help identify patients who will respond to treatment.

Source

Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin Cancer Res. 2021;27:3926-3935.

Related Items
First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Gastrointestinal Cancers, Checkpoint Inhibitors
Nivolumab Demonstrates Significant Overall Survival Benefits in Patients with Previously Treated Esophageal Squamous-Cell Carcinoma Compared with Chemotherapy
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Trifluridine/Tipiracil and Ramucirumab Demonstrate Antitumor Activity in Previously Treated Unresectable Advanced Gastric or Gastroesophageal Cancer
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Insertion-Deletion Rate Is Associated with Clinical Outcomes in Nivolumab-Treated Gastric Cancer
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Surufatinib in Combination with Toripalimab Demonstrates Antitumor Responses in Previously Treated Patients with Gastric or Gastroesophageal Adenocarcinoma
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Ramucirumab plus Paclitaxel Confers an Overall Survival Advantage Over Placebo in the RAINBOW-Asia Study
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Zolbetuximab in Combination with Epirubicin/Oxaliplatin/Capecitabine Shows Survival Advantage in Patients with Gastric, Gastroesophageal Junction, and Esophageal Cancer: The FAST Study
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Second-Line Nivolumab with Paclitaxel plus Ramucirumab Shows Promising Antitumor Responses in Patients with Advanced Gastric Cancer
Web Exclusives published on December 14, 2021 in Gastrointestinal Cancers
Health-Related Quality-of-Life Scores Higher in Patients with Advanced Gastric Cancer, Esophageal Adenocarcinoma, or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy
Web Exclusives published on November 17, 2021 in Gastrointestinal Cancers
First-Line Pembrolizumab plus Chemotherapy Improves Overall Survival and Progression-Free Survival in Patients with Advanced Esophageal Cancer
Web Exclusives published on November 17, 2021 in Gastrointestinal Cancers
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: